MAP2K1 and acute lymphoblastic leukemia: Selumetinib, a MEK1/2 inhibitor, was tested against 46 solid tumor and ALL PDXs on a twice daily x 5 and once daily x 2 schedule for an intended 6 weeks at a dose of 100 mg/kg (Kolb et al., 2010).